Cesca Therapeutics To Present At The H.C. Wainwright 21st Annual Global Investment Conference

Tuesday, September 3, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

RANCHO CORDOVA, Calif., Sept. 3, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced Jeff Cauble, Vice President of Finance and Principal Accounting Officer, will present at the H.C. Wainwright 21st Annual Global Investment Conference

on Tuesday, September 10 at 12:30 pm ET. The conference is being held September 8-10 at the Lotte New York Palace Hotel.

Management will also be available for one-on-one meetings with institutional investors who are registered to attend the conference.  Institutional investors who would like to attend Cesca's presentation or meet with management can register through the H.C. Wainwright conference portal or contact Rx Communications to schedule a meeting.

About Cesca Therapeutics Inc.Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis develops, commercializes and markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The company has developed an automated, functionally-closed CAR-TXpress™ platform to streamline the manufacturing process for the emerging CAR-T immunotherapy market. For more information about Cesca, please visit: www.CescaTherapeutics.com. For additional information about ThermoGenesis, please visit: www.thermogenesis.com.

Company Contact: Wendy Samford916-858-5191ir@thermogenesis.com 

Investor Contact: Paula Schwartz, Rx Communications917-322-2216pschwartz@rxir.com

Cision View original content:http://www.prnewswire.com/news-releases/cesca-therapeutics-to-present-at-the-hc-wainwright-21st-annual-global-investment-conference-300910094.html

SOURCE Cesca Therapeutics Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store